Sign In
Buy CCXI
$10.24
+0.0150 (+0.147%)
At Close: Jun 03, 2026
2 Beaten-Down Biotech Stocks That Could Bounce Back
06:13am, Tuesday, 27'th Jul 2021
The market hasn't been kind to these two drugmakers, but both have a chance to turn things around.
ChemoCentryx: CRL Less Likely
11:04am, Sunday, 25'th Jul 2021
In my previous coverage, I said many analysts including myself thought a CRL was likely for avacopan. However, the FDA has accepted an amendment to the NDA and given an October 7 PDUFA date.
Is Now the Time to Buy ChemoCentryx Stock?
06:44am, Saturday, 10'th Jul 2021
Analysts following this risky biotech stock have changed their tune.
ChemoCentryx (CCXI) Files Amendment to NDA for Avacopan
10:32am, Wednesday, 07'th Jul 2021
ChemoCentryx (CCXI) files an amendment to its NDA for avacopan for treatment of ANCA-associated vasculitis. The new PDUFA date is Oct 7.
SAN DIEGO, July 7, 2021 /PRNewswire/ -- Johnson Fistel, LLP is investigating potential claims on behalf of ChemoCentryx Inc. ("ChemoCentryx" or the "Company") (NASDAQ: CCXI) against certain of its c
Why This ChemoCentryx Analyst Is Bullish
03:20pm, Tuesday, 06'th Jul 2021
H.C. Wainwright analysts remain bullish on ChemoCentryx, Inc. (NASDAQ:CCXI) following an amended new drug application for avacopan. The ChemoCentryx Analyst: Edward White reaffirmed a Buy rating on
ChemoCentryx Stock Is Approaching A Key Level
01:55pm, Tuesday, 06'th Jul 2021
ChemoCentryx Inc. (NASDAQ: CCXI) shares traded higher Tuesday after the company announced it filed an amendment to its New Drug Application for avacopan for the treatment of anti-neutrophil cytoplasmi
New York, New York--(Newsfile Corp. - July 6, 2021) - The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of ChemoCentryx, Inc.Shareholders w
New York, New York--(Newsfile Corp. - July 6, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of ChemoCentryx, Inc. (NASDAQ: CCXI) between November
ChemoCentryx Stock Jumps On Amendment In Avacopan Application, New Goal Date Of October 7
09:17am, Tuesday, 06'th Jul 2021
Following consultations with the FDA, ChemoCentryx Inc (NASDAQ: CCXI) filed an amendment to its marketing application seeking approval for avacopan to treat Anti-neutrophil Cytoplasmic Autoantibod
Los Angeles, California--(Newsfile Corp. - July 6, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ChemoCentryx, Inc. ("
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ChemoCentryx, Inc. - CCXI
10:35pm, Monday, 05'th Jul 2021
New York, New York--(Newsfile Corp. - July 5, 2021) - Pomerantz LLP is investigating claims on behalf of investors of ChemoCentryx, Inc. ("ChemoCentryx" or the "Company") (NASDAQ: CCXI). Such investor
CCXI LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving ChemoCentryx, Inc.
06:18pm, Monday, 05'th Jul 2021
New York, New York--(Newsfile Corp. - July 5, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased ChemoCentryx, Inc. ("Chemo
New York, New York--(Newsfile Corp. - July 5, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of ChemoCentryx, Inc. (NASDAQ: CCXI) alleging
Kessler Topaz Meltzer & Checker, LLP: Final Deadline Reminder for ChemoCentryx, Inc. Investors - CCXI
10:10am, Monday, 05'th Jul 2021
RADNOR, Pa., July 5, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed against ChemoCentryx, Inc. (NASDAQ: C
